CMVLF
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.17 | $6M | -$16M |
| 2025 Q4 | -0.26 | $10M | -$11M |
| 2025 Q3 | 0.01 | $35M | -$3M |
| 2025 Q2 | -0.25 | $17M | -$11M |
| 2025 Q1 | -0.18 | $11M | -$18M |
| 2024 Q4 | 0.06 | $13M | -$2M |
| 2024 Q3 | -0.23 | $16M | -$7M |
| 2024 Q2 | -0.28 | $8M | $50M |